The University of Pennsylvania Cancer Research Training Program prepares the next generation of cancer researchers by providing protected time in an environment dedicated to the enhancement of research skills and concepts. The Cancer Center has demonstrated its ability to consistently meet the aims of the training program throughout the past fifteen years. Currently, all but one of the trainees who completed training on this grant during the current period are, or will be, full-time faculty in academic medicine. ? ? Six post-doctoral trainees, who have completed their training in the clinical aspects of medical oncology, pediatric oncology, radiation oncology or pathology receive two years of research training in contemporary biomedical or clinical investigation under the tutelage of senior scientists. These experienced research mentors are drawn from the Cancer Center's Basic Research Programs (Immunology, Virology, Cell and Molecular Biology, Cancer Genetics) and Clinical Investigations Programs (e.g., Cancer Pharmacology and Experimental Therapeutics; Cancer Epidemiology and Biostatistics). The training program is specifically designed to select, prepare, and motivate trainees to pursue academic positions in oncology. The integrated curriculum involves formal course work, research seminars and conferences, lecture series, and supervised research projects. Those pursuing clinical research are expected to complete a Master's level curriculum in either Cancer Pharmacology or in Cancer Epidemiology and Biostatistics (including genetic epidemiology, outcomes research or bioethics). An Executive Committee oversees trainee selection and recruitment, the training program, and evaluates individual trainee progress. ? ? The Cancer Center is a long-standing NCI-designated Comprehensive Cancer Center, and is recognized for its interdisciplinary research programs, integration of basic and clinical investigation, and patient care. Fourteen Shared Resources facilitate cancer investigation. Extensive trainee research opportunities spanning all aspects of cancer research are available through the University of Pennsylvania and its School of Medicine, The Children's Hospital of Philadelphia, Wistar Institute, and Veterans' Administration Medical Center, all of which have an outstanding record in cancer research and are located on a single campus. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009615-19
Application #
7472300
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1988-08-01
Project End
2010-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
19
Fiscal Year
2008
Total Cost
$359,205
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Richman, Sarah A; Nunez-Cruz, Selene; Moghimi, Babak et al. (2018) High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunol Res 6:36-46
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Bosse, Kristopher R; Raman, Pichai; Zhu, Zhongyu et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12
Bosse, Kristopher R; Maris, John M (2016) Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122:20-33
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Wilson, Melissa A; Guld, Kelly; Galetta, Steven et al. (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66
Shah, Nirav N; Casella, Erica; Capozzi, Donna et al. (2016) Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract 12:e71-6
Pauken, Kristen E; Sammons, Morgan A; Odorizzi, Pamela M et al. (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160-1165

Showing the most recent 10 out of 85 publications